Fri, Oct 24, 2014, 11:55 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

  • pfein2012 pfein2012 Nov 13, 2012 10:33 AM Flag

    This is a most useless board!

    This is a most useless board full of one liners sitting in front of a monitor watching the price of CUR and posting out of sheer excitement.
    Take today's move, rather than looking for news or considering technical analysis or some intelligent question/answer, all we get is pumping and cheering.

    Before you longs start name calling, I am long and bullish on CUR. Now you longs go ahead and insult me.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Also CUR was mentioned in a "blog" about SRPT as to whether or not "retail" can scoop analysts on share price appreciation and results in biotechs due to new technology of social media, etc. IMO

      Lately I`ve been watching shares of Neuralstem (CUR). The company recently completed a phase I trial testing NSI-566, a mixture of human neural stem cells injected directly into a patients lumbar or cervical spinal cord for the treatment of Amyotrophic Lateral Sclerosis (ALS). The phase I trial was a 15 patient open-label design. Neuralstem published preliminary results from the first 12 patients of the trial in Stem Cells (2012;30:1144-1151). Since that time, three new patients and three returning patients have received new injections of NSI-566.

      Analysis of the ongoing phase 1 trial in ALS continues. The final patient was treated with five unilateral cervical injections in August 2012. The last three patients treated (patients #16, #17, and #18) all previously completed ten bilateral lumbar spinal cord injections (patients #10, #11, and #12). The data published in Stem Cell showed clear signs of disease stabilization in a subset of ambulatory patients on the ALS Functional Rating Scale (ALSFRS-R), as well as a Forced Vital Capacity (FVC) and Hand-Held Dynamometer (HHD) scales. If we know anything about ALS, it`s that it is a rapidly progressive and degenerative disease. Patients do not spontaneously stabilize.

      One patient (#11), named Ted Harada, showed significant improvement in motor function. Mr. Harada`s improvements were so much so that he was able to walk without a cane. Physicians even had to re-diagnose his disease to confirm ALS after his unprecedented improvement following lumbar spinal cord injections of NSI-566.

      Similar to what we saw above with Sarepta and eteplirsen, Mr. Harada discussed his results with local media (source). An article by Crain`s Detroit Business (link) highlighted the success of Mr. Harada, and another ALS patient, Ed Tessaro, after receiving another round of treatment. There`s even a video interview of both Mr. Harada and Mr. Tessaro discussing their experiences with NSI-566. Continue reading by clicking here.

    • Just what are you looking for on this MB, mister? Doctoral dissertations on stem cell research, etc.?
      MAKE SENSE! If U don't like it here - just go away .......... it's 2nd grade common sense!

      Sentiment: Strong Buy

    • joe_vish Nov 13, 2012 10:45 AM Flag

      Why dont you take a minute and give your take on today's positive day and why it happened?

      Sentiment: Strong Buy

      • 1 Reply to joe_vish
      • .Fair enough! Here is my take in today's price spike.
        1-My search of about 15min did not find any "relevant" news.
        2-Volume and trade voracity plus individual trade-size and block trades (shown in my setup and easy to monitor) seemed bullish and sustainable.
        3-Further, and encouraging, CUR had dropped to a low of 0.88 prior to the rise which I saw and see as bullish. It is my experience that prior to substantial gains price dips (or is it made so?) and such was the case today.

        And now I have to go to work. Good luck to all

        Sentiment: Strong Buy

2.77-0.04(-1.42%)Oct 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.